Antidepressants

From Biogenic Amines to New Mechanisms of Action
Herausgegeben:Macaluso, Matthew; Preskorn, Sheldon H.

• Gebundenes Buch

Produktbeschreibung

This volume reviews the known neurobiology of depression and combines classic data on antidepressant treatments with modern theory on the physiology of depression. It also discusses novel mechanism of action drugs.

Produktdetails

• Handbook of Experimental Pharmacology 250
• Verlag: Springer / Springer International Publishing / Springer, Berlin
• Artikelnr. des Verlages: 978-3-030-10948-6
• 1st ed. 2019
• Seitenzahl: 456
• Erscheinungstermin: 17. Juni 2019
• Englisch
• Abmessung: 241mm x 160mm x 30mm
• Gewicht: 838g
• ISBN-13: 9783030109486
• ISBN-10: 3030109488
• Artikelnr.: 54648032

Inhaltsangabe

Part 1: Overview and General Principles.- 1. Impact, Diagnosis, Phenomenology, and Biology.- Part 2: The Past - from antiquity to 1970 including TCAs and MAOIs.- 2. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?.- Part 3: The Present- 1970 to 2016.- 3. Clinical Implications of the STAR D Trial.- 4. Pharmacogenomics and Biomarkers of Depression.- 5. Therapeutic Drug Monitoring of Antidepressants.- 6. Selective Serotonin Reuptake Inhibitors.- 7. Serotonin and Norepinephrine Reuptake Inhibitors.- 8. Neurostimulation Therapies.- 9. Current Role of Herbal and Natural Preparations.- Part 4: The future.- 10. Role of Inflammation in Depression and Treatment Implications.- 11. NMDA Antagonists for Treatment-Resistant Depression.- 12. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.- 13. Other Antidepressants.- Part 5: Use of Antidepressants in Special Populations.- 14. Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders.- 15. Treatment of Depression in Women.- 16. Management of Late-Life Depression.- 17. The Use of Antidepressants in Bipolar Depression.

---

Part 1: Overview and General Principles.- 1. Impact, Diagnosis, Phenomenology, and Biology.- Part 2: The Past - from antiquity to 1970 including TCAs and MAOIs.- 2. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?.- Part 3: The Present- 1970 to 2016.- 3. Clinical Implications of the STAR*D Trial.- 4. Pharmacogenomics and Biomarkers of Depression.- 5. Therapeutic Drug Monitoring of Antidepressants.- 6. Selective Serotonin Reuptake Inhibitors.- 7. Serotonin and Norepinephrine Reuptake Inhibitors.- 8. Neurostimulation Therapies.- 9. Current Role of Herbal and Natural Preparations.- Part 4: The future.- 10. Role of Inflammation in Depression and Treatment Implications.- 11. NMDA Antagonists for Treatment-Resistant Depression.- 12. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.- 13. Other Antidepressants.- Part 5: Use of Antidepressants in Special Populations.- 14. Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders.- 15. Treatment of Depression in Women.- 16. Management of Late-Life Depression.- 17. The Use of Antidepressants in Bipolar Depression.

---

Part 1: Overview and General Principles.- 1. Impact, Diagnosis, Phenomenology, and Biology.- Part 2: The Past – from antiquity to 1970 including TCAs and MAOIs.- 2. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?.- Part 3: The Present- 1970 to 2016.- 3. Clinical Implications of the STAR*D Trial.- 4. Pharmacogenomics and Biomarkers of Depression.- 5. Therapeutic Drug Monitoring of Antidepressants.- 6. Selective Serotonin Reuptake Inhibitors.- 7. Serotonin and Norepinephrine Reuptake Inhibitors.- 8. Neurostimulation Therapies.- 9. Current Role of Herbal and Natural Preparations.- Part 4: The future.- 10. Role of Inflammation in Depression and Treatment Implications.- 11. NMDA Antagonists for Treatment-Resistant Depression.- 12. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.- 13. Other Antidepressants.- Part 5: Use of Antidepressants in Special Populations.- 14. Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders.- 15. Treatment of Depression in Women.- 16. Management of Late-Life Depression.- 17. The Use of Antidepressants in Bipolar Depression.